[HTML][HTML] Direct cardiac effects of SGLT2 inhibitors
S Chen, R Coronel, MW Hollmann, NC Weber… - Cardiovascular …, 2022 - Springer
Abstract Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large
cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure …
cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure …
Heart failure in type 2 diabetes mellitus: impact of glucose-lowering agents, heart failure therapies, and novel therapeutic strategies
HC Kenny, ED Abel - Circulation research, 2019 - Am Heart Assoc
Patients with diabetes mellitus have> 2× the risk for developing heart failure (HF; HF with
reduced ejection fraction and HF with preserved ejection fraction). Cardiovascular …
reduced ejection fraction and HF with preserved ejection fraction). Cardiovascular …
[HTML][HTML] SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects
A Tentolouris, P Vlachakis, E Tzeravini… - International journal of …, 2019 - mdpi.com
Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular
(CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of …
(CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of …
[HTML][HTML] Diabetic cardiomyopathy: current and future therapies. Beyond glycemic control
G Borghetti, D Von Lewinski, DM Eaton… - Frontiers in …, 2018 - frontiersin.org
Diabetes mellitus and the associated complications represent a global burden on human
health and economics. Cardiovascular diseases are the leading cause of death in diabetic …
health and economics. Cardiovascular diseases are the leading cause of death in diabetic …
Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart
Aims Emipagliflozin (EMPA) is a potent inhibitor of the renal sodium-glucose co-transporter
2 (SGLT2) and an effective treatment for type-2 diabetes. In patients with diabetes and heart …
2 (SGLT2) and an effective treatment for type-2 diabetes. In patients with diabetes and heart …
Class effects of SGLT2 inhibitors on cardiorenal outcomes
AY Kluger - Textbook of Cardiorenal Medicine, 2021 - Springer
Background: This chapter will summarize the four recent sodium-glucose cotransporter 2
inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI …
inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI …
Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats
A Aragon-Herrera, S Feijoo-Bandin… - Biochemical …, 2019 - Elsevier
Abstract The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in
patients with Type 2 Diabetes Mellitus (T2DM)) trial made evident the potentiality of …
patients with Type 2 Diabetes Mellitus (T2DM)) trial made evident the potentiality of …
Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium
D Cappetta, A De Angelis, LP Ciuffreda… - Pharmacological …, 2020 - Elsevier
The results of trials with sodium-glucose cotransporter 2 (SGLT2) inhibitors raised the
possibility that this class of drugs provides cardiovascular benefits independently from their …
possibility that this class of drugs provides cardiovascular benefits independently from their …
Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways
Clinical trials with sodium–glucose cotransporter 2 (SGLT2) inhibitors (empagliflozin,
dapagliflozin, and canagliflozin) have shown a decrease in the progression of chronic …
dapagliflozin, and canagliflozin) have shown a decrease in the progression of chronic …
[HTML][HTML] SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
DD Adingupu, SO Göpel, J Grönros, M Behrendt… - Cardiovascular …, 2019 - Springer
Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) is the first class of anti-
diabetes treatment that reduces mortality and risk for hospitalization due to heart failure. In …
diabetes treatment that reduces mortality and risk for hospitalization due to heart failure. In …